等待开盘 08-07 09:30:00 美东时间
+0.057
+0.18%
Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences
08-05 04:41
Minovia Therapeutics reports positive interim results from its Phase 2 trial of MNV-201 for Pearson Syndrome, showing a favorable safety profile and early signs of efficacy in three patients. Two compassionate use patients with Kearns-Sayre syndrome also demonstrated improved quality of life. The FDA has granted Fast Track and Rare Pediatric Disease Designations to MNV-201. Minovia plans to finalize enrollment in the trial and advance toward pivo...
07-24 12:15